Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study

European Journal of Cancer

Volumn 48, Issue 10, 2012, Pages 1512-1518

  Oudard, Stéphane ^a   Thiam, Rokhaya ^a   Fournier, Laure S ^a   Medioni, Jacques ^a   Lamuraglia, Michele ^a   Scotte, Florian ^a   Fabre, Elizabeth ^a   Kim, Dennis ^b   Kpamegan, Euloge ^b   Panneerselvam, Ashok ^b   Cuenod, Charles A ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Kidney cancer; mTOR; Oncology; RAD001; RECIST; Sequential therapy; Targeted therapy

Indexed keywords

EVEROLIMUS; PLACEBO; SORAFENIB; SUNITINIB;

CANCER SURVIVAL; HUMAN; KIDNEY METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862781223     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.027     Document Type: Article

References (14)

1. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 2000 205 216
2. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134
3. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 22 2009 3584 3590
4. L.S. Fournier, S. Oudard, and R. Thiam Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT Radiology 256 2 2010 511 518
5. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
6. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 18 2010 4256 4265
7. S. Oudard, J. Medioni, and J. Aylllon Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma Expert Rev Anticancer Ther 9 6 2009 705 717
8. R. Thiam, L.S. Fournier, and L. Trinquart Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib Ann Oncol 21 5 2010 936 941
9. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 13 2007 1760 1764
10. W.L. Monsky, V. Raptopoulos, and M.T. Keogan Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method Eur Radiol 14 3 2004 519 525
11. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
12. D. Cella Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma Oncologist 16 Suppl. 2 2011 23 31
13. D. Cella Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes Cancer Treat Rev 35 8 2009 733 737
14. D. Cella, J.C. Cappelleri, and A. Bushmakin Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa J Oncol Pract 5 2 2009 66 70